April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal Erythropoietin in Eyes with Geographic Atrophy Secondary to Age-related Macular Degeneration
Author Affiliations & Notes
  • Stephen H Sinclair
    Ophthalmology, Sinclair Retina Associates, Media, PA
    Ophthalmology, Drexel University School Medicine, Philadelphia, PA
  • Kelly Hurley
    Ophthalmology, Sinclair Retina Associates, Media, PA
  • Britt Parvus
    Ophthalmology, Sinclair Retina Associates, Media, PA
  • Peter Presti
    Interactive Multi-media Technology Center, Georgia Institute of Technology, Atlanta, GA
  • Footnotes
    Commercial Relationships Stephen Sinclair, Interactive Medical Imaging Technologies (P), Sinclair Technologies (P); Kelly Hurley, None; Britt Parvus, None; Peter Presti, Sinclair Technoloigies, LLC (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5890. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephen H Sinclair, Kelly Hurley, Britt Parvus, Peter Presti; Intravitreal Erythropoietin in Eyes with Geographic Atrophy Secondary to Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5890.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To investigate the role of Procrit intravitreal injections in stabilizing vision and geographic atrophy (GA) in eyes with atrophic AMD and to characterize SDOCT and central visual field acuity perimetry (Omnifield) findings associated with GA that threatened or had recently involved the foveola.


A retrospective pilot study examined eyes treated off-label with Procrit 5U injected intravitreal every 6 weeks. Photographed GA areas (identified on autofluorescence and fluorescein angiogram images) were manually outlined and the area converted to sq mm using the OCT caliper. SDOCT images were analyzed for loss of PR ellipsoid-segment, loss of ONL, and RPE thickening. Primary outcomes were the effect of treatment on rates per year of GA enlargement and changes in Omnifield fixation acuity, the best acuity in 6 degrees of fixation and Global Macular Acuity (weighted average of threshold acuities within 10° of fixation). GA enlargement rate was also compared between treated eyes and fellow untreated eyes with similar GA.


32 eyes of 28 patients were treated for 1.6±0.85 yrs with 12.2±6.2 injections. Eyes were followed for 0.75±0.36 yrs prior to treatment with avg initial GA area of 10.2±7.0 sq mm. Treatment reduced the rate of GA enlargement by 0.67±0.2.0 sq mm/y (56%) from 2.55±3.8 sq mm/y prior to treatment. In 24 untreated fellow eyes, GA enlargement was 2.25±0.89msq mm/y, or 0.32±0.38 sq mm/y larger than in treated eyes. In the treated eyes visual acuity over the term improved by an average 0.1 logMAR +/-0.30 logMAR with no significant difference from the fellow untreated eyes. Omnifiled GMA improved an average of 0.16±0.09logMAR during treatment compared with a loss of 0.05±0. prior to treatment. GA was described by OCT loss of PR ellipsoid segment junction and ONL. Indicators of future GA progression were loss of ONL and RPE thickening at the margins. Central acuity visual field scotomas corresponded with loss of PR ellipsoid segment.


In this off-label study, intravitreal Procrit® appears to slow progressive GA expansion and vision loss in AMD. Acuity perimetry and OCT are useful for mapping areas of preserved vision, monitoring disease progression, and predicting future GA enlargement.

Keywords: 585 macula/fovea • 550 imaging/image analysis: clinical • 615 neuroprotection  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.